Recent evidence on modifiable and non-modifiable risk factors for colorectal cancer (CRC): a systematic synopsis of meta-analyses from 2015 to 2017

  • Teguh Kristian Perdamaian Faculty of Medicine, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia; Centre of Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom
DOI: https://doi.org/10.13181/mji.v28i2.2679
Keywords: colorectal cancer, genetic marker, metabolic disease, meta-analysis, risk factors
Abstract viewed: 774 times
PDF downloaded: 780 times
HTML downloaded: 127 times
EPUB downloaded: 238 times

Abstract

Colorectal cancer (CRC) is a common cancer with a huge impact on international public health. This review discusses recent evidence on modifiable and non-modifiable risk factors for CRC using a systematic review method. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines on systematic reviews and meta-analyses of observational studies. The literature search was performed on the Ovid MEDLINE database and included publications from 2015 to 2017, followed by a quality assessment and a narrative synthesis. Of the 90 identified articles, there were 13 meta-analyses with statistically significant results. Seven articles discussed modifiable risk factors and six articles discussed non-modifiable risk. The modifiable risk factors with the highest risk were radiotherapy of prostate cancer (pooled odds ratio 1.68; 95% confidence interval [CI] 1.33-2.12). The non-modifiable risk factors with the highest risk was Lynch syndrome (hazard ratio 135.49; 95% CI 111.55-164.57). This review discovered new and previously known risk factors for CRC. Recent evidence shows that research on CRC risk factors is continuing to grow indicating that more studies on risk factors are needed to optimize CRC prevention and early detection.

Downloads

Download data is not yet available.

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210

  2. Douaiher J, Ravipati A, Grams B, Chowdhury S, Alatise O, Are C. Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol. 2017;115(5):619-30. https://doi.org/10.1002/jso.24578

  3. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-48.

  4. Pruitt SL, Shim MJ, Mullen PD, Vernon SW, Amick BC 3rd. Association of area socioeconomic status and breast, cervical, and colorectal cancer screening: a systematic review. Cancer Epidemiol Biomarkers Prev. 2009;18(10):2579-99. https://doi.org/10.1158/1055-9965.EPI-09-0135

  5. Wheat CL, Clark-Snustad K, Devine B, Grembowski D, Thornton TA, Ko CW. Worldwide incidence of colorectal cancer, leukemia, and lymphoma in inflammatory bowel disease: an updated systematic review and meta-analysis. Gastroenterol Res Pract. 2016;2016:1632439. https://doi.org/10.1155/2016/1632439

  6. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666-89. https://doi.org/10.1136/gut.2009.179804

  7. National Guideline C. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. 2016.

  8. Porta M, Greenland S, Hernán M, dos Santos Silva I, Last JM. A Dictionary of Epidemiology: Oxford University Press; 2014.

  9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097

  10. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama R, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851. https://doi.org/10.1136/bmj.i851

  11. Jayasekara H, MacInnis RJ, Room R, English DR. Long-term alcohol consumption and breast, upper aero-digestive tract and colorectal cancer risk: a systematic review and meta-analysis. Alcohol Alcohol. 2016;51(3):315-30. https://doi.org/10.1093/alcalc/agv110

  12. Zhang C, Zhong M. Consumption of beer and colorectal cancer incidence: a meta-analysis of observational studies. Cancer Causes Control. 2015;26(4):549-60. https://doi.org/10.1007/s10552-015-0532-5

  13. Luo G, Zhang Y, Wang L, Huang Y, Yu Q, Guo P, et al. Risk of colorectal cancer with hysterectomy and oophorectomy: a systematic review and meta-analysis. Int J Surg. 2016;34:88-95. https://doi.org/10.1016/j.ijsu.2016.08.518

  14. Guraya SY. Association of type 2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review. World J Gastroenterol. 2015;21(19):6026-31. https://doi.org/10.3748/wjg.v21.i19.6026

  15. Zhao Y, Wang X, Wang Y. Helicobacter pylori infection and colorectal carcinoma risk: a meta-analysis. J Cancer Research Ther. 2016;12(Supplement):15-8. https://doi.org/10.4103/0973-1482.191621

  16. Jenkins MA, Dowty JG, Ait Ouakrim D, Mathews JD, Hopper JL, Drouet Y, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. J Clin Oncol. 2015;33(4):326-31. https://doi.org/10.1200/JCO.2014.55.8536

  17. Chen H, Shen Z, Hu Y, Xiao Q, Bei D, Shen X, et al. Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis. J Cancer Res Clin Oncol. 2015;141(12):2147-58. https://doi.org/10.1007/s00432-015-1976-4

  18. Li M, Gu Y. Quantitative assessment of the influence of common variation rs16892766 at 8q23.3 with colorectal adenoma and cancer susceptibility. Mol Genet Genomics. 2015;290(2):461-9. https://doi.org/10.1007/s00438-014-0928-z

  19. Tu L, Yan B, Peng Z. Common genetic variants (rs4779584 and rs10318) at 15q13.3 contributes to colorectal adenoma and colorectal cancer susceptibility: evidence based on 22 studies. Mol Genet Genomics. 2015;290(3):901-12. https://doi.org/10.1007/s00438-014-0970-x

  20. Wang L, Qian J, Ying C, Zhuang Y, Shang X, Xu F. X-ray cross-complementing groups 1 rs1799782 C>T polymorphisms and colorectal cancer susceptibility: a meta-analysis based on Chinese Han population. J Cancer Res Ther. 2016;12(Supplement):C264-7. https://doi.org/10.4103/0973-1482.200753

  21. Zhou L, Xie J, Gu EL, Huang Y, Qu Y, Xu AP, et al. Common genetic variant on BMP4 contributes to colorectal adenoma and cancer: a meta-analysis based on 15 studies. Cytokine. 2015;72(2):154-9. https://doi.org/10.1016/j.cyto.2014.12.021

  22. Luo S, Li JY, Zhao LN, Yu T, Zhong W, Xia ZS, et al. Diabetes mellitus increases the risk of colorectal neoplasia: an updated meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40(1):110-23. https://doi.org/10.1016/j.clinre.2015.05.021

  23. Takam R, Bezak E, Yeoh EE. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model. Phys Med Biol. 2009;54(3):611-25. https://doi.org/10.1088/0031-9155/54/3/009

  24. Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110(11):1696-701. https://doi.org/10.1111/j.1464-410X.2012.11385.x

  25. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999;93(5 Pt 2):880-8. https://doi.org/10.1016/S0029-7844(98)00424-4

  26. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis. World J Gastroenterol. 2013;19(6):936-45. https://doi.org/10.3748/wjg.v19.i6.936

  27. Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Nagata C, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44(10):986-99. https://doi.org/10.1093/jjco/hyu108

  28. Chen YS, Xu SX, Ding YB, Huang XE, Deng B. Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev. 2013;14(12):7613-9. https://doi.org/10.7314/APJCP.2013.14.12.7613

  29. Zumkeller N, Brenner H, Zwahlen M, Rothenbacher D. Helicobacter pylori infection and colorectal cancer risk: a meta-analysis. Helicobacter. 2006;11(2):75-80. https://doi.org/10.1111/j.1523-5378.2006.00381.x

  30. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011; 22(9):1958-72. https://doi.org/10.1093/annonc/mdq653

  31. Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167(12):1397-406. https://doi.org/10.1093/aje/kwn073

  32. Li X, Yao X, Wang Y, Hu F, Wang F, Jiang L, et al. MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features. PLoS One. 2013;8(3):e59064. https://doi.org/10.1371/journal.pone.0059064

  33. Wang T, Liu Y, Sima L, Shi L, Wang Z, Ni C, et al. Association between MLH1 -93G>a polymorphism and risk of colorectal cancer. PLoS One. 2012;7(11):e50449. https://doi.org/10.1371/journal.pone.0050449

  34. Mao D, Zhang Y, Lu H, Fu X. Association between X-ray repair cross-complementing group 1 Arg194Trp polymorphism and colorectal cancer risk. Tumour Biol. 2013;34(5):2529-38. https://doi.org/10.1007/s13277-013-0760-9

  35. Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34(1):555-63. https://doi.org/10.1007/s13277-012-0581-2

  36. Sun A, Liu R, Sun G. Insulin therapy and risk of colorectal cancer: an updated meta-analysis of epidemiological studies. Curr Med Res Opin. 2014;30(3):423-30. https://doi.org/10.1185/03007995.2013.858622

  37. Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, et al. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget. 2017;8(9):16017-26. https://doi.org/10.18632/oncotarget.13762

  38. Nie Z, Zhu H, Gu M. Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. Pharm Biol. 2016;54(11):2636-42. https://doi.org/10.1080/13880209.2016.1176057

  39. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4(1):9-22. https://doi.org/10.1158/1940-6207.CAPR-10-0262

Published
2019-08-09
How to Cite
1.
Perdamaian TK. Recent evidence on modifiable and non-modifiable risk factors for colorectal cancer (CRC): a systematic synopsis of meta-analyses from 2015 to 2017. Med J Indones [Internet]. 2019Aug.9 [cited 2024Jul.3];28(2):188-95. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/2679
Issue
Vol. 28 No. 2 (2019): June
Section
Review Article

Copyright (c) 2019 Teguh Kristian Perdamaian

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.